LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics, Inc. (NASDAQ: CRTX), a biopharmaceutical company focused on developing and commercializing innovative products for respiratory, inflammatory and critical care diseases, today announced the receipt of a $5.0 million milestone payment from Dey, L.P. (DEY), a subsidiary of Mylan Inc. The payment is part of a co-promotion agreement between the companies for ZYFLO CRTM (zileuton) extended-release tablets, Critical Therapeutics’ twice-daily formulation for the prophylaxis and chronic treatment of asthma in adults 12 years of age and older.
